Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant Charcot-Marie-Tooth disease type 2N (CMT2N) is a mild form of axonal Charcot-Marie-Tooth disease, a peripheral sensorimotor neuropathy, characterized by distal legs sensory loss and weakness that can be asymmetric. Tendon reflexes are reduced in the knees and absent in ankles. Progression is slow.
Features include always present findings: Distal muscle weakness; and common findings: Hyporeflexia, Lower limb muscle weakness, Distal sensory impairment, and Absent Achilles reflex and others. 14 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Muscles | 4 | Skeletal muscle atrophy, Distal muscle weakness, Lower limb muscle weakness |
Arms and legs | 3 | Lower limb muscle weakness, Foot dorsiflexor weakness, Distal lower limb amyotrophy |
Brain and nerves | 2 | Peripheral axonal neuropathy, Hyporeflexia |
Bones and joints | 1 | Skeletal muscle atrophy |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
AARS1 encodes alanyl-tRNA synthetase 1 (968 aa). Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala). Highest expression in Cells EBV-transformed lymphocytes (212.7 TPM) and Cells Cultured fibroblasts (191.4 TPM).
Charcot-Marie-Tooth disease axonal type 2N is caused by mutations in the AARS1 gene on chromosome 16.
AARS1 is classified as a druggable target (Enzyme category) with score 0.6.
90 pathogenic variants reported in AARS1 in ClinVar, including hotspot variant LRG_359p1:p.Arg329His (2-star review).
Variant | Significance | Review Stars | Hotspot |
|---|---|---|---|
LRG_359p1:p.Arg329His | Pathogenic | 2 stars | Yes |
Genetic testing for AARS1 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 1 always present feature, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease axonal type 2N. Research spans Review / Meta-Analysis (100%).
Zhou XY (2026). [PMID: 41639505](https://pubmed.ncbi.nlm.nih.gov/41639505/). *Discov Oncol*. [Review / Meta-Analysis]
Zhang H (2025). [PMID: 39487674](https://pubmed.ncbi.nlm.nih.gov/39487674/). *IUBMB Life*. [Review / Meta-Analysis]
Mahmood M (2025). [PMID: 40156251](https://pubmed.ncbi.nlm.nih.gov/40156251/). *IUBMB Life*. [Review / Meta-Analysis]
Data assembled from 9 of 12 sources · Last updated Sep 20, 2026, 1:47 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease axonal type 2N
AI-curated news mentioning Charcot-Marie-Tooth disease axonal type 2N
Updated Apr 12, 2026
A recent study published in PubMed highlights a rare case of mucosal bleeding in a newborn, revealing an unusual combination of Type 2A and Type 2N von Willebrand Disease. This research contributes to the understanding of bleeding disorders in neonates.